Solid state forms of HDAC inhibitors

The present disclosure relates to crystalline mesylate Form 1 of N-hydroxy-2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo [3.1. 0] hex-3-yl} pyrimidine-5-carboxamide and a process for the preparation thereof. The crystalline mesylate Form 1 of N-hydroxy-2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo [3.1. 0] hex-3-yl} pyrimidine-5-carboxamide may be used in the preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders, and inflammation. 本公开涉及N-羟基2-{6-[(6-氟-喹啉-2-基甲基)-氨基]-3-氮杂-双环[3.1.0]己-3-基}嘧啶-5-甲酰胺的结晶甲磺酸盐形式1及其制备方法。N-羟基2-{6-[(6-氟-喹啉-2-基甲基)-氨基]-3-氮杂-双环[3.1.0]己-3-基}嘧啶-5-甲酰胺的结晶甲磺酸盐形式1可用于制备用于治疗癌症、免疫障碍和炎症的药物组合物和剂型。